These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20031714)

  • 1. Long-term paclitaxel-eluting stent outcomes in elderly patients.
    Forman DE; Cox DA; Ellis SG; Lasala JM; Ormiston JA; Stone GW; Turco MA; Wei JY; Joshi AA; Dawkins KD; Baim DS
    Circ Cardiovasc Interv; 2009 Jun; 2(3):178-87. PubMed ID: 20031714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
    Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries.
    Lasala JM; Cox DA; Dobies D; Baran K; Bachinsky WB; Rogers EW; Breall JA; Lewis DH; Song A; Starzyk RM; Mascioli SR; Dawkins KD; Baim DS;
    Circ Cardiovasc Interv; 2009 Aug; 2(4):285-93. PubMed ID: 20031730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes after differential use of drug-eluting stents in diabetic patients: 1-year results from the DES.DE (Drug-Eluting Stent.DEutschland) registry.
    Akin I; Bufe A; Eckardt L; Reinecke H; Richardt G; Kuck KH; Senges J; Schneider S; Nienaber CA;
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):50-7. PubMed ID: 20578192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials.
    Kirtane AJ; Ellis SG; Dawkins KD; Colombo A; Grube E; Popma JJ; Fahy M; Leon MB; Moses JW; Mehran R; Stone GW
    J Am Coll Cardiol; 2008 Feb; 51(7):708-15. PubMed ID: 18279734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete versus incomplete revascularization in patients with multivessel disease undergoing percutaneous coronary intervention with drug-eluting stents.
    Tamburino C; Angiolillo DJ; Capranzano P; Dimopoulos K; La Manna A; Barbagallo R; Tagliareni F; Mangiafico S; Guzman LA; Galassi AR; Bass TA
    Catheter Cardiovasc Interv; 2008 Oct; 72(4):448-56. PubMed ID: 18814218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usage patterns and 2-year outcomes with the TAXUS express stent: results of the US ARRIVE 1 registry.
    Lasala JM; Cox DA; Dobies D; Muhlestein JB; Katopodis JN; Revtyak G; Baim DS;
    Catheter Cardiovasc Interv; 2008 Oct; 72(4):433-45. PubMed ID: 18814217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-hospital complications and long-term outcomes of the paclitaxel drug-eluting stent in acute ST-elevation myocardial infarction: a real-world experience from a high-volume medical center.
    Shammas NW; Shammas GA; Hahn A; Jerin M; Dippel EJ; Winter M
    Cardiovasc Revasc Med; 2009; 10(3):151-5. PubMed ID: 19595395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: results from the Prairie "Real World" Stent Registry.
    Goswami NJ; Gaffigan M; Berrio G; Plessa AL; Pfeiffer AM; Markwell SJ; Mishkel GJ
    Catheter Cardiovasc Interv; 2010 Jan; 75(1):93-100. PubMed ID: 19787803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
    Stone GW; Moses JW; Ellis SG; Schofer J; Dawkins KD; Morice MC; Colombo A; Schampaert E; Grube E; Kirtane AJ; Cutlip DE; Fahy M; Pocock SJ; Mehran R; Leon MB
    N Engl J Med; 2007 Mar; 356(10):998-1008. PubMed ID: 17296824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry).
    Hanna NN; Gaglia MA; Torguson R; Ben-Dor I; Gonzalez MA; Collins SD; Syed AI; Maluenda G; Kaneshige K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Waksman R
    Am J Cardiol; 2010 Aug; 106(4):504-10. PubMed ID: 20691308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction.
    Slottow TL; Steinberg DH; Roy P; Javaid A; Buch AN; Okabe T; Xue Z; Smith K; Torguson R; Pichard AD; Satler LF; Suddath WO; Kent KM; Waksman R
    Cardiovasc Revasc Med; 2008; 9(1):24-8. PubMed ID: 18206634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
    Laynez A; Sardi G; Hauville C; Barbash IM; Pakala R; Torguson R; Xue Z; Satler LF; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):759-65. PubMed ID: 22488756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry.
    Lee JY; Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Park SW; Park SJ
    J Am Coll Cardiol; 2009 Aug; 54(9):853-9. PubMed ID: 19695467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry.
    Williams DO; Abbott JD; Kip KE;
    Circulation; 2006 Nov; 114(20):2154-62. PubMed ID: 17060386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of length and diameter of drug-eluting stents versus bare-metal stents on late outcomes.
    Applegate RJ; Sacrinty MT; Kutcher MA; Santos RM; Gandhi SK; Little WC
    Circ Cardiovasc Interv; 2009 Feb; 2(1):35-42. PubMed ID: 20031691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting stents in the elderly: long-term (> one year) clinical outcomes of octogenarians in the DESIRE (Drug-Eluting Stents In the REal world) registry.
    Costa JR; Sousa A; Moreira AC; Costa RA; Maldonado G; Cano MN; Egito ET; Romano ER; Barbosa M; Pavanello R; Jardim C; Cury A; Berwanger O; Sousa JE
    J Invasive Cardiol; 2008 Aug; 20(8):404-10. PubMed ID: 18688065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.